PFIZER INC
PFENYSEDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for PFE
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for PFE
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 4 Aug 2026
Q2 Adjusted EPS Meets Expectations
Reported adjusted diluted EPS of $0.77 for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $0.68.
Revenue Guidance Raised
Pfizer raised its full-year 2026 revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion.
EPS Guidance Reaffirmed
The company reaffirmed its full-year 2026 adjusted diluted EPS guidance of $2.80 to $3.00, which absorbs an impact of approximately $0.10 related to the Innovent Biologics transaction.
Operational Revenue Growth
Focused execution drove 18% year-over-year operational revenue growth from launched and acquired products in the second quarter.
No Share Repurchases Planned
No share repurchases have been completed in 2026, and current financial guidance does not anticipate any repurchases for the remainder of the year.
Vaccine Pipeline Milestone
A pivotal Phase 3 pediatric program for the 25-valent pneumococcal conjugate vaccine candidate PF-07872412 began in May 2026 following positive Phase 2 results.
Price Chart
NYSE:PFE via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
PFEPFIZER INC | $27.96 | $159.4B | — | 9.4x | -0.2% | 73.2% | 6.9% |
Company Profile
About the Company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Next Earnings Date
Nov 3, 2026
Loading latest news...